hUC-MSCs Therapy with EVs Booster Improves Recovery in Stage 2 Chronic Kidney Disease with Hypercholesterolemia : a case report
Abstract
Hypercholesterolemia is a common metabolic comorbidity that accelerates the progression of chronic kidney disease (CKD). Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and their secretome, which consist of extracellular vecicles (EVs) and soluble bioactive molecules, have shown potential in modulating inflammation and metabolism. This case report describes significant improvement in serum lipid profile following hUC-MSC and secretome therapy in a patient with stage 2 CKD and hypercholesterolemia. A male patient with CKD stage 2 received two intravenous cycles of hUC-MSC and secretome therapy administered seven months apart. Serial evaluations demonstrated a progressive decline in total cholesterol from 294 mg/dL at baseline to 286 mg/dL after the first treatment and 225 mg/dL after the second. LDL cholesterol decreased from 188 mg/dL to 140 mg/dL, with a mild rebound to 175 mg/dL. HDL cholesterol, initially elevated at 214 mg/dL, showed a modest increase to 220 mg/dL after the first treatment, followed by normalization to 175 mg/dL. Triglyceride levels remained within the normal range (44–51 mg/dL) throughout the observation period. The marked improvement in lipid parameters suggests that hUC-MSC and secretome therapy may exert systemic metabolic regulation via anti-inflammatory, antioxidative, and hepatoprotective mechanisms. hUC-MSC and secretome administration demonstrated potential benefits in lipid homeostasis in a patient with CKD and hypercholesterolemia. These findings support the role of MSC-derived secretome as a promising adjunctive therapeutic approach. Larger controlled trials are warranted to confirm these outcomes and elucidate underlying mechanisms.
References
2. Chastagner, D., Arnion, H., Danthu, C., Touré, F., & Picard, N. (2024). Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions. Pharmacogenomics, 25(16–18), 707–718. https://doi.org/10.1080/14622416.2025.2470613
3. Golchin, A., Chatziparasidou, A., Ranjbarvan, P., Niknam, Z., & Ardeshirylajimi, A. (2020). Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges (pp. 19–37). https://doi.org/10.1007/5584_2020_592
4. Habiba, U. E., Khan, N., Greene, D. L., Ahmad, K., Shamim, S., & Umer, A. (2024). Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. Frontiers in Endocrinology, 15. https://doi.org/10.3389/fendo.2024.1380443
5. Kawabori, M., Shichinohe, H., Kuroda, S., & Houkin, K. (2020). Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke. International Journal of Molecular Sciences, 21(19), 7380. https://doi.org/10.3390/ijms21197380
6. Pimentel, A. L., Bauer, A. C., & Camargo, J. L. (2015). Renal posttransplantation diabetes mellitus: An overview. Clinica Chimica Acta, 450, 327–332. https://doi.org/10.1016/j.cca.2015.09.010
7. Zhang, Z., Sun, J., Guo, M., & Yuan, X. (2023). Progress of new-onset diabetes after liver and kidney transplantation. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1091843
8. Balarini, C. M., Oliveira, M. Z. T., Pereira, T. M. C., Silva, N. F., Vasquez, E. C., Meyrelles, S. S., & Gava, A. L. (2011). Hypercholesterolemia promotes early renal dysfunction in apolipoprotein E-deficient mice. Lipids in Health and Disease, 10(1), 220.
9. Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 12(1), 7–11.
10. Levey, A. S., & Coresh, J. (2012). Chronic kidney disease. The Lancet, 379(9811), 165–180.
11. Lindoso, R. S., Collino, F., Bruno, S., Araujo, D. S., Sant’Anna, J. F., Tetta, C., Provero, P., Quesenberry, P. J., Vieyra, A., & Einicker-Lamas, M. (2014). Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury. Stem Cells and Development, 23(15), 1809–1819.
12. Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Del Vecchio, L., De Nicola, L., Leoncini, G., Mallamaci, F., & Zoccali, C. (2020). Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 33(3), 417–430.
13. Reiss, A. B., Voloshyna, I., De Leon, J., Miyawaki, N., & Mattana, J. (2015). Cholesterol metabolism in CKD. American Journal of Kidney Diseases, 66(6), 1071–1082.
14. Wanner, C., & Tonelli, M. (2014). KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303–1309.
15. Mutlu, A. S., Duffy, J., & Wang, M. C. (2021). Lipid metabolism and lipid signals in aging and longevity. Developmental cell, 56(10), 1394–1407. https://doi.org/10.1016/j.devcel.2021.03.034
16. Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024). Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review. Journal of Personalized Medicine, 14(9), 996. https://doi.org/10.3390/jpm14090996
17. Chen, H., Chen, X., Zhou, Z., Zheng, J., Lu, Y., Lin, P., Lin, Y., Zheng, Y., Xiong, B., Xu, R., Cui, L., & Zhao, X. (2025). Mesenchymal stromal cell-mediated mitochondrial transfer unveils new frontiers in disease therapy. Stem Cell Research & Therapy, 16(1). https://doi.org/10.1186/s13287-025-04675-x
18. Lin, Y. H., Kang, L., Feng, W. H., Cheng, T. L., Tsai, W. C., Huang, H. T., Lee, H. C., & Chen, C. H. (2020). Effects of Lipids and Lipoproteins on Mesenchymal Stem Cells Used in Cardiac Tissue Regeneration. International journal of molecular sciences, 21(13), 4770. https://doi.org/10.3390/ijms21134770
19. Yu, L., Xue, J., Wu, Y., & Zhou, H. (2023). Therapeutic effect of exosomes derived from hepatocyte-growth-factor-overexpressing adipose mesenchymal stem cells on liver injury. Folia histochemica et cytobiologica, 61(3), 160–171. https://doi.org/10.5603/fhc.95291
20. Műzes, G., & Sipos, F. (2022). Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases. Cells, 11(15), 2300. https://doi.org/10.3390/cells11152300
Copyright (c) 2025 International Journal of Cell and Biomedical Science

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.